Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program
Authors
Cutrona, Sarah L.Toh, Sengwee
Iyer, Aarthi
Foy, Sarah
Daniel, Gregory W.
Nair, Vinit P.
Ng, Daniel
Butler, Melissa G.
Boudreau, Denise M.
Forrow, Susan
Goldberg, Robert J.
Gore, Joel M.
McManus, David D.
Racoosin, Judith A.
Gurwitz, Jerry H.
UMass Chan Affiliations
Department of Medicine, Division of Cardiovascular MedicineMeyers Primary Care Institute
Department of Medicine, Division of Geriatric Medicine
Document Type
Journal ArticlePublication Date
2013-01-01Keywords
Myocardial InfarctionAlgorithms
Outcome Assessment (Health Care)
UMCCTS funding
Cardiology
Cardiovascular Diseases
Health Services Administration
Health Services Research
Metadata
Show full item recordAbstract
PURPOSE: To validate an algorithm based upon International Classification of Diseases, 9(th) revision, Clinical Modification (ICD-9-CM) codes for acute myocardial infarction (AMI) documented within the Mini-Sentinel Distributed Database (MSDD). METHODS: Using an ICD-9-CM-based algorithm (hospitalized patients with 410.x0 or 410.x1 in primary position), we identified a random sample of potential cases of AMI in 2009 from four Data Partners participating in the Mini-Sentinel Program. Cardiologist reviewers used information abstracted from hospital records to assess the likelihood of an AMI diagnosis based on criteria from the Joint European Society of Cardiology and American College of Cardiology Global Task Force. Positive predictive values (PPVs) of the ICD-9-based algorithm were calculated. RESULTS: Of the 153 potential cases of AMI identified, hospital records for 143 (93%) were retrieved and abstracted. Overall, the PPV was 86.0% (95% confidence interval; 79.2%, 91.2%). PPVs ranged from 76.3% to 94.3% across the four Data Partners. CONCLUSIONS: The overall PPV of potential AMI cases, as identified using an ICD-9-CM-based algorithm, may be acceptable for safety surveillance; however, PPVs do vary across Data Partners. This validation effort provides a contemporary estimate of the reliability of this algorithm for use in future surveillance efforts conducted using the Food and Drug Administration's MSDD. Copyright © 2012 John Wiley & Sons, Ltd.Source
Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):40-54. doi: 10.1002/pds.3310. Link to article on publisher's site
DOI
10.1002/pds.3310Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37181PubMed ID
22745038Related Resources
ae974a485f413a2113503eed53cd6c53
10.1002/pds.3310